Text Size

Evaluation of the Proliferative Activities of Insulin Analogues in Primary Human Tumor Cells

Expanded access is currently available for this treatment.
Verified August 2012 by Meir Medical Center
Sponsor:
Collaborator:
Tel Aviv University
Information provided by (Responsible Party):
Meir Medical Center
ClinicalTrials.gov Identifier:
NCT01267461
First received: December 27, 2010
Last updated: August 9, 2012
Last verified: August 2012
History of Changes
  Purpose

Recently the general medical literature has become aware that the use of certain long-acting insulin analogues could potentially increase cancer risk.During the last few years the investigators group generated information of both scientific and clinical relevance on the proliferative and anti-apoptotic actions of insulin analogues. The goal of this project is to evaluate the hypothesis that the proliferative and signalling activities elicited by insulin analogues may have a impact on tumor behavior. In this study the investigators will asses the biological actions of insulin analogs in primary tumor cells of endometrial and colon cancer.


Condition Intervention
Endometrial Cancer
Colon Cancer
 Other: Tissue sample from tumor

Study Type: Expanded Access     What is Expanded Access?

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Meir Medical Center:

Intervention Details:
    Other: Tissue sample from tumor
    Endometrial cancer specimens will be obtained from patients operated and treated at the Gynecologic Oncology Unit at Meir Medical Center. Colon cancer specimens will be obtained from patients that underwent colonoscopy at the Gastrointestinal Department at Meir Medical Center.
  Eligibility

Ages Eligible for Study:   18 Years to 90 Years
Genders Eligible for Study:   Female
Criteria

Inclusion Criteria:

  • Patients with Endometrial and Colon Cancer

Exclusion Criteria:

  • None
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01267461

Contacts
Contact: Ilan Bruchim, MD 972-9-7472561 ilan.bruchim@clalit.org.il

Sponsors and Collaborators
Meir Medical Center
Tel Aviv University
  More Information

No publications provided

Responsible Party: Meir Medical Center
ClinicalTrials.gov Identifier: NCT01267461     History of Changes
Other Study ID Numbers: 0015-10-MMC
Study First Received: December 27, 2010
Last Updated: August 9, 2012
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration

Keywords provided by Meir Medical Center:
To asses the biological actions of insulin analogs in primary tumor cells

Additional relevant MeSH terms:
Colonic Neoplasms
Endometrial Neoplasms
Adenoma
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
 Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Uterine Diseases
Genital Diseases, Female
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type

ClinicalTrials.gov processed this record on June 17, 2013